ISGIDAR June 15th, 2024
International Study Group Investigating Drugs as Reinforcers
Square Dorchester, 2nd Floor

7:45 – 8:30  Coffee and Registration
8:30 – 8:35  Opening Remarks
8:35 – 9:00  Richard A. Meisch, Colin N. Haile, and Therese A. Kosten
Drugs as reinforcers. Misconceptions and methodological errors
9:00 – 9:25  Bill Fantegrossi, Brenda Gannon, Hannah Shaw, Kayla Wolf, Marina Avram, and Jeff Moran
Synthetic fentanyl analogs as oral reinforcers in mice: A matter of taste
9:25 – 9:50  Cesar Ramon Romero Leguizamon, and Morgane Thomsen
Do I feel comfortable attached to a fiber photometry patch cord?
ISGIDAR Travel Award Recipient (Sponsored by Suzette Evans and Richard Foltin)
9:50 – 10:10  Coffee Break
10:10 – 10:35  Hannah N. Carlson, Samantha P. Armas, Jacob D. Camp, and Mark A. Smith
The positive reinforcing effects of cocaine and opposite-sex social contact
ISGIDAR Travel Award Recipient (Sponsored by Suzette Evans and Richard Foltin)
10:35 – 11:00  Emily M. Jutkiewicz, Ashleigh Matthews, Aaron Ajlen, Lucy Joying, Kenner C. Rice
(Re)Evaluating the reinforcing effects of the delta opioid receptor agonist SNC80 in rodents
11:00 – 12:00  Wendy J. Lynch
Shifts in the role of positive versus negative reinforcement in addiction
President’s Invited Lecture
12:00 – 1:00  Lunch
1:00 – 1:25  Matthew L. Banks, and Madison M. Marcus
Effects of independent vs. dependent schedules on fentanyl vs. shock avoidance/escape choice in rats
1:25 – 1:50  Lindsey K. Galbo-Thomma, Carly Baehr, Marco Pravetoni, and Charles P. France
A monoclonal antibody selectively attenuates fentanyl and carfentanil self-administration in rhesus monkeys
William Woolverton Travel Award Recipient (Historically sponsored by Woolverton trainees; this year: Karen Anderson, Mike Nader, Sally Huskinson)
1:50 – 2:15  Emma Childs
A comparison of two alcohol self-administration paradigms in moderate-heavy drinkers
2:15 – 2:35  Afternoon Break
2:35 – 3:00  Sandra D. Comer, Shanna Babalonis, Jermaine D. Jones, Paul A. Nuzzo, and Sharon L. Walsh
A randomized, double-blind, placebo- and active-controlled, crossover study to evaluate the abuse potential of oxymorphone compared to other mu opioid agonists in physically dependent opioid users with moderate-to-severe opioid use disorder (FDA BAA-17-000123)
3:00 – 4:00  Panel, Abuse potential assessment of novel substances with putatively low abuse potential
Chair and co-moderator: Jack E. Henningfield
Discussant and co-moderator: Sandra D. Comer
Panelists: Justin C. Strickland, James K. Rowlett, and Ziva D. Cooper
4:00 – 4:30  Business Meeting